Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2022-04-08 Share Issue/Capital Cha…
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Registration of new share capital
Share Issue/Capital Change Classification · 98% confidence The document explicitly states 'Registration of new share capital' and details the resulting increase in the company's share capital (NOK 2,900,694.09, divided into 290,069,409 shares). This directly relates to a change in the company's capital structure through the registration of new shares following a warrant exercise. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). The document length is very short (440 chars), but the content is a definitive statement of a capital change registration, not merely an announcement that a report is attached, making SHA a more specific fit than RPA or RNS.
2022-04-08 English
Nykode Therapeutics - full year 2021 financial results and corporate presentation
Investor Presentation Classification · 95% confidence The document is titled 'FY 2021 Presentation' and contains slides detailing management, pipeline progress, financial results (Income Statement and Balance Sheet excerpts), and organizational structure. The content strongly suggests a comprehensive review of the past fiscal year's performance and future outlook, presented to investors or stakeholders. This format is characteristic of an Annual Report presentation or a detailed Investor Presentation summarizing the annual results. Since it is explicitly labeled as a 'Presentation' and includes detailed financial tables and operational updates, it aligns best with an Investor Presentation (IP) summarizing the annual performance, rather than the formal 10-K filing itself, or a brief Earnings Release (ER). Given the depth of pipeline and financial data, IP is the most appropriate classification over a simple ER or RPA.
2022-04-01 English
Nykode Therapeutics - full year 2021 financial results and corporate presentation
Earnings Release Classification · 99% confidence The document is titled "Company Announcement" and explicitly states it concerns the "full year 2021 financial results and corporate presentation." It announces a webcast presentation scheduled for April 1, 2022, and mentions that the "slide presentation is attached to this announcement and is also available in the Investors section." Since the document is short (3337 chars) and its primary function is to announce the availability of the financial results presentation (which is attached/linked), it fits the definition of a Report Publication Announcement (RPA) rather than the full financial report (10-K) or the presentation itself (IP). FY 2021
2022-04-01 English
Nykode Therapeutics - full year 2021 financial results and corporate presentation
Investor Presentation Classification · 99% confidence The document is titled "Nykode Therapeutics - full year 2021 financial results and corporate presentation" and announces a webcast presentation of the 2021 financial results scheduled for April 1, 2022. Crucially, the text states, "The slide presentation is attached to this announcement and is also available in the Investors section..." The document itself is short (3364 chars) and serves primarily to announce the availability of the presentation and the associated webcast, rather than being the full financial report (10-K) or the presentation itself (IP). This fits the definition of a Report Publication Announcement (RPA): "Announcement regarding the timing, release, or publication of company reports (often stating the report is attached or available on the website)." It is announcing the release of the 'corporate presentation' and 'financial results' presentation.
2022-04-01 English
Mandatory notification of exercise of warrants and sale of shares to primary insider’s related party
Director's Dealing Classification · 98% confidence The document text details transactions involving a 'person discharging managerial responsibilities' (Einar J. Greve, a Board member) concerning shares and warrants in the issuer (Nykode Therapeutics AS and Vaccibody AS). Specifically, it reports the 'Exercise of warrants' and 'Sale of shares to closely associated enterprise' and 'Acquisition of shares' by an associated entity. This structure—reporting transactions by insiders (managers/directors) regarding their holdings—is characteristic of regulatory filings concerning insider trading or director's dealings, often mandated by market regulations (like MAR in Europe). The closest matching category is 'Director's Dealing' (DIRS).
2022-03-31 English
Mandatory notification of exercise of warrants and sale of shares to primary insider’s related party
Director's Dealing Classification · 95% confidence The document explicitly states it is a 'Mandatory notification of exercise of warrants and sale of shares to primary insider’s related party'. This involves transactions by a director (Einar J. Greve) involving his own shares/options (warrants) and subsequent sale to a related party. This falls under the definition of Director's Dealing (insider trades). The document is very short (496 chars) and directs the reader to an 'attached document' for further details, suggesting it is an announcement rather than the full regulatory filing itself. However, the core subject matter is insider transactions, which maps directly to 'Director's Dealing' (DIRS). Since the text describes the transaction itself rather than just announcing the publication of a standard regulatory form (like a 10-K or 10-Q), DIRS is the most specific fit, even though it is brief.
2022-03-31 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.